^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Chronic Myelomonocytic Leukemia
    Drug:Inqovi (decitabine/cedazuridine) (DNMT inhibitor, Cytidine deaminase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    ASH 2022
    Title:

    854 Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

    Published date:
    11/03/2022
    Excerpt:
    133 subjects with MDS/CMML were enrolled to ASCERTAIN and were randomly assigned either IV decitabine for cycle 1 and oral decitabine/cedazuridine for cycle 2 or the opposite treatment sequence....The median OS and LFS of the TP53mut population were 25.5 and 22.1 mo., respectively, compared to the TP53 WT group with mOS and LFS estimates 33.7 and 31.7 months, respectively...ASCERTAIN trial included 35% with TP53mut and this group had a worse survival than those with WT TP53...
    DOI:
    https://doi.org/10.1182/blood-2022-163841
    Trial ID:
    Ascertain